Analysis of Clinical Benefit Using DNG64- <i>CAR-V</i> Chimeric Tumor Targeted Amphotropic RNA Vector in <i>CCNG1</i> Expressing Cancers
A response rate of 50% and a CBR of 90% for all groups meet the Simon 2-stage threshold of CBR >30%, thereby qualifying all groups for a Phase II study using DNG64-<i>CAR-V</i>+ in <i>CCNG1</i> expressing advanced cancers.
Authors
- Erlinda M. Gordon (ORCID: https://orcid.org/0000-0003-2599-7188)
- Howard W. Bruckner (ORCID: https://orcid.org/0000-0002-7459-7255)
- Paul Y. Song (ORCID: https://orcid.org/0009-0004-3270-0324)
- Stefaan Van Gool (ORCID: https://orcid.org/0000-0002-8102-5968)
- Kambiz Nael (ORCID: https://orcid.org/0000-0002-4194-9488)
- Samantha Jeffrey (ORCID: https://orcid.org/0009-0004-9650-7443)
- Neal Shiv Chawla (ORCID: https://orcid.org/0000-0001-7863-7958)
- Sant P. Chawla (ORCID: https://orcid.org/0000-0002-9522-6744)
- Anna M. Gattani
- Rheanna Carter
- Jennifer Kosmal
- Frederick L. Hall
- ROBIN L. JONES
- SKYLER S. PANG
- CHARLES B. SIMONE
- TIMO HUBER
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- Gere Foundation (US)
- 490 BioTech (United States) (US)
- Sarcoma Oncology Center (US)
- New York Proton Center (US)
- Addgene (US)
- New York Oncology Hematology (US)
- Royal Marsden Hospital (GB)
- California Medical Clinic for Headache (US)
- Centrum für Integrierte Onkologie (DE)
- University of San Francisco (US)
- Repligen (United States) (US)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.21873/anticanres.18091
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00